BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current assets$3.97 BCurrent liabilities$1.66 BLiabilities$5.40 BAssets$11.72 BNon-current liabilities$3.74 BNon-current assets$7.75 BEquity$6.32 BGross equity(calculated)$6.34 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSInventoryAccounts receivable, netCash and cash equivalentsOther current assetsIntangible assets, netProperty, plant and equipment, netDeferred tax assetsGoodwillOther assetsAccounts payable and accrued liabilitiesCurrent portion of long-term debt, netLong-term debt, netOther long-term liabilitiesAdditional paid-in capitalRetained earningsCommon stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Company common stock held by the Nonqualified Deferred Compensation PlanAccumulated other comprehensive lossCurrent assetsCurrent assets$3.97 BCurrent liabilitiesCurrent liabilities$1.66 BAccounts payable and accrued liabilitiesAccounts payable and accrued liabilities$1.01 BInventoryInventory$1.78 BLiabilitiesLiabilities$5.40 BCurrent portion of long-term debt, netCurrent portion of long-term debt, net$658.20 MAccounts receivable, netAccounts receivable, net$1.06 BAssetsAssets$11.72 BCash and cash equivalentsCash and cash equivalents$874.01 MNon-current liabilitiesNon-current liabilities$3.74 BLong-term debt, netLong-term debt, net$3.53 BOther current assetsOther current assets$254.05 MOther long-term liabilitiesOther long-term liabilities$209.82 MNon-current assetsNon-current assets$7.75 BEquityEquity$6.32 BIntangible assets, netIntangible assets, net$4.88 BGross equity (calculated)Gross equity(calculated)$6.34 BProperty, plant and equipment, netProperty, plant and equipment, net$989.99 MAdditional paid-in capitalAdditional paid-in capital$6.04 BDeferred tax assetsDeferred tax assets$888.58 MGoodwillGoodwill$655.75 MRetained earningsRetained earnings$304.50 MOther assetsOther assets$338.14 MCommon stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectivelyCommon stock$194.00 KCompany common stock held by the Nonqualified Deferred Compensation PlanCompany common stock held by theNonqualified Deferred Compensation Plan−$11.23 MAccumulated other comprehensive lossAccumulated other comprehensive loss−$8.78 M
Chart details

BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
11,723,442,000 US dollars
Current assets
3,971,623,000 US dollars
Non-current assets
7,751,819,000 US dollars
Liabilities
5,401,750,000 US dollars
Current liabilities
1,663,996,000 US dollars
Non-current liabilities
3,737,754,000 US dollars
Equity
6,321,692,000 US dollars
Inventory
1,782,524,000 US dollars
Accounts receivable, net
1,061,047,000 US dollars
Cash and cash equivalents
874,005,000 US dollars
Other current assets
254,047,000 US dollars
Short-term investments
0 US dollars
Intangible assets, net
4,879,367,000 US dollars
Property, plant and equipment, net
989,994,000 US dollars
Deferred tax assets
888,575,000 US dollars
Goodwill
655,745,000 US dollars
Other assets
338,138,000 US dollars
Long-term investments
0 US dollars
Accounts payable and accrued liabilities
1,005,793,000 US dollars
Current portion of long-term debt, net
658,203,000 US dollars
Long-term debt, net
3,527,939,000 US dollars
Other long-term liabilities
209,815,000 US dollars
Additional paid-in capital
6,037,019,000 US dollars
Retained earnings
304,495,000 US dollars
Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively
194,000 US dollars
Company common stock held by the Nonqualified Deferred Compensation Plan
negative 11,233,000 US dollars
Accumulated other comprehensive loss
negative 8,783,000 US dollars
Gross equity (calculated)
6,341,708,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!